Bayer Launches myMentor Peer-to-Peer Support Program

Bayer announced today the launch of myMentor, a US peer-to-peer support program for adult patients with pulmonary arterial hypertension (PAH, WHO Group 1) or chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4). The program was announced today during the Pulmonary Hypertension Association International PH Conference and Scientific Sessions in Orlando. “Being diagnosed with a rare, progressive and debilitating disease can be confusing and even frightening for some patients despite guidance from their healthcare provider,” said Aleksandra Vlajnic, M.D., Vice President of Medical Affairs, Bayer. “Our hope is that myMentor will provide an additional layer of support and emotional reassurance that only patients who have had similar experiences can provide one another, especially during the start of treatment and lifestyle adjustment.”

Patients with PAH and CTEPH would welcome more information for themselves and caregivers about these rare diseases when first diagnosed. myMentor is designed to help patients who have not yet been prescribed a treatment or have started treatment but still have questions about living with these diseases or conditions, and who may benefit from conversations with peers who can offer support and insights along the treatment journey. Patients can go to mymentorprogram.com to speak privately and confidentially with a mentor who lives with either PAH or CTEPH. Patients undergoing treatment should always speak with their healthcare provider. For additional details and to register for myMentor, go to mymentorprogram.com, email [email protected] or call (866) 758-7682. – Medical Buyer Bureau